类风湿性关节炎药物市场－全球产业规模、份额、趋势、机会及预测（依分子类型、药物类别、通路、地区及竞争格局划分，2021-2031年）

全球类风湿性关节炎治疗市场预计将从 2025 年的 597.1 亿美元成长到 2031 年的 855.2 亿美元，复合年增长率为 6.17%。

该类药物包括非类固醇消炎剂、皮质类固醇和缓解疾病抗风湿药，所有这些药物都旨在抑制免疫介导的发炎并保护关节结构。全球人口老化和自体免疫疾病发生率上升是推动市场成长的主要因素，因为这些疾病需要长期持续的药物治疗。此外，诊断技术的进步使得疾病的早期发现成为可能，从而有效增加了符合治疗性介入的患者数量。

然而，生物製剂的高成本给该行业带来了许多挑战，生物製药，导致低成本生物相似药进入市场，蚕食了部分市场份额。风湿性疾病负担之重凸显了有效管理风湿性疾病的迫切性。根据美国关节炎基金会预测，到2025年，美国将有约6,000万成年人被诊断出患有某种类型的关节炎，凸显了製定强有力的治疗策略的迫切需求。

市场驱动因素

推动市场成长的关键因素之一是生物製药和标靶合成缓解疾病抗风湿药物（DMARDs）的日益普及，因为医疗服务提供者正在寻求比传统治疗方法缓解率更高的治疗方案。医生越来越多地选择具有创新作用机制的药物，例如JAK抑制剂，这类药物能够快速缓解症状并预防关节结构损伤。这种追求高品质、高效疗法的趋势也反映在财务表现上。根据艾伯维公司于2025年10月发布的“2025年第三季财务业绩”，JAK抑制剂RINVOQ的全球净销售额飙升至21.84亿美元，增幅达35.3%，这主要得益于销量和市场份额的增长。这显示临床上对标靶治疗有着强烈的偏好。

同时，全球人口快速老化也成为持续的市场驱动力，因为老年人更容易罹患与类风湿性关节炎相关的自体免疫疾病。这种人口结构的变化需要製定长期管理策略，并显着增加药物消耗。根据2025年4月发表在《免疫学前沿》（Frontiers in Immunology）上的一份报告，全球老年人类风湿性关节炎的盛行率估计为790万例，凸显了对可扩展老年护理日益增长的需求。为了控制不断增长的患者群体所带来的成本，医疗保健系统正在转向更具成本效益的解决方案。正如Evernorth Health Services在2025年8月指出的那样，从2024年底到2025年初，发炎性疾病的生物相似药索赔增加了46.5%，这表明治疗选择正朝着更容易取得的方向发展。

市场挑战

生物製药的高昂成本，加上关键药物专利到期以及随之而来的生物类似药涌入，为类风湿性关节炎领域的收入成长带来了巨大障碍。生物製药通常定价较高，加重了医疗预算的负担，并阻碍了其在财政资源有限地区的市场渗透。随着这些重磅药物的专利保护期结束，价格更低廉的生物相似药迅速进入市场，加剧了竞争，迫使原厂药公司降价或放弃市场份额。虽然这种动态可能增加接受治疗的患者数量，但往往会缩小市场的整体价值。

近期产业数据显示，生物相似药的成本效益提升，也印证了收入下降的影响。根据美国可及药品协会（Association for Accessible Medicines）预测，到2025年，生物相似药的使用将为美国医疗保健系统每年节省202亿美元。这笔巨额收入其实已从品牌药市场消失。因此，儘管价格更低廉的替代药物的普及提高了患者获得治疗的机会，但也直接阻碍了全球类风湿性关节炎治疗药物市场的增长，因为利润率高的原研药销售被利润率较低的学名药和生物类似药销售所取代。

市场趋势

基于生物标记的精准医疗正在变革治疗策略，使其从试验处方模式转向基于分子谱的个人化医疗。这项转变满足了早期识别对昂贵生物製药无反应患者的迫切需求，从而优化临床疗效并减少经济浪费。 Cipher Medicine公司于2025年6月宣布了一项重要的进展。该公司宣布，他们利用人工智慧驱动的演算法分析了约1500名类风湿性关节炎患者的真实临床数据，并识别出能够准确预测治疗成功的临床指标。此类创新使医生能够选择最适合每位患者独特生物学特征的作用机制，从而实现超越常规治疗指南的治疗方案。

同时，将数位健康工具整合到医疗服务中，以增强即时症状监测并提高用药依从性，已成为强劲的趋势。随着疾病管理越来越依赖复杂的自我管理疗法，行动应用程式对于弥合医疗咨询与日常自我护理之间的鸿沟至关重要。然而，维持长期、持续的参与度仍然是一个挑战。 2025年12月发表在《风湿病国际》（Rheumatology International）上的一项研究调查了2036名成年用户，发现只有25.8%的用户达到了12週的持续遵从性标准。这项发现印证了业界致力于开发更直观、以患者为中心的数位平台，以确保处方疗法的全部临床益处能够透过持续使用得以实现。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球类风湿性关节炎治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依分子类型（药品、生物药品）
  • 依药物类别（非类固醇消炎剂（NSAIDs）、缓解疾病抗风湿药（DMARDs）、皮质类固醇、镇痛药、其他）
  • 通路（处方药、非处方药）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美类风湿性关节炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲类风湿性关节炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区类风湿性关节炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲类风湿性关节炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美类风湿性关节炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球类风湿性关节炎药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Rheumatoid Arthritis Drugs Market is projected to expand from USD 59.71 Billion in 2025 to USD 85.52 Billion by 2031, reflecting a compound annual growth rate of 6.17%. This pharmaceutical sector encompasses nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs, all designed to suppress immune-mediated inflammation and protect joint structure. Market growth is fundamentally supported by an aging global population and the rising incidence of autoimmune disorders, which demand consistent, long-term pharmacological management. Furthermore, advancements in diagnostic technologies are enabling earlier detection of the disease, effectively increasing the number of patients eligible for therapeutic intervention.

Conversely, the industry faces substantial hurdles due to the high cost of biologic therapies, which limits accessibility in price-sensitive regions and places a strain on healthcare budgets. This difficulty is compounded by the expiration of patents for major biologic agents, resulting in market erosion as lower-cost biosimilars become available. The urgency for effective rheumatic disease management is highlighted by the sheer burden of the condition; according to the Arthritis Foundation, approximately 60 million adults in the United States were reported to be living with doctor-diagnosed arthritis in 2025, underscoring the critical need for robust treatment strategies.

Market Driver

A primary catalyst for market expansion is the growing adoption of biologics and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), as healthcare providers seek therapies with superior remission rates compared to traditional options. Physicians are increasingly favoring agents with innovative mechanisms of action, such as JAK inhibitors, which offer rapid symptom relief and prevent structural joint damage. This trend toward premium, high-efficacy therapeutics is reflected in financial performance; according to AbbVie's 'Third-Quarter 2025 Financial Results' from October 2025, global net revenues for the JAK inhibitor Rinvoq surged to $2.184 billion, a 35.3% increase driven by volume growth and market share gains, demonstrating a strong clinical preference for targeted interventions.

Simultaneously, the rapidly aging global population acts as a sustained driver for the market, given the elderly's heightened susceptibility to the autoimmune dysregulation associated with rheumatoid arthritis. This demographic shift requires long-term management strategies, significantly boosting the consumption of therapeutic agents. As reported by Frontiers in Immunology in April 2025, the global prevalence of rheumatoid arthritis among the elderly was estimated at 7.9 million cases, emphasizing the growing need for scalable geriatric care. To manage the costs associated with this expanding patient base, systems are turning to cost-effective solutions; Evernorth Health Services noted in August 2025 that biosimilar claims for inflammatory conditions rose by 46.5% between late 2024 and early 2025, indicating a pivot toward accessible treatment options.

Market Challenge

The substantial cost of biologic therapies, combined with the patent expiration of key drugs and the subsequent influx of biosimilars, creates a significant barrier to revenue growth in the rheumatoid arthritis sector. Biologics typically carry premium price tags, which burden healthcare budgets and restrict market penetration in regions with limited financial resources. As exclusivity protections for these blockbuster drugs lapse, affordable biosimilars rapidly enter the market, intensifying competition and compelling originator companies to lower prices or cede market share. This dynamic leads to a contraction in overall market value, even as the volume of patients receiving treatment may increase.

The impact of this revenue erosion is confirmed by recent industry data regarding cost savings. According to the Association for Accessible Medicines, the utilization of biosimilar medicines in 2025 generated $20.2 billion in savings for the U.S. healthcare system over the prior year. This figure represents a substantial amount of revenue effectively removed from the branded pharmaceutical market. Consequently, while the availability of cheaper alternatives improves patient access to care, it directly hinders the financial expansion of the Global Rheumatoid Arthritis Drugs Market by replacing high-margin therapeutic revenue with lower-value generic and biosimilar sales.

Market Trends

The integration of biomarker-driven precision medicine is transforming therapeutic strategies, moving the field from trial-and-error prescription models toward personalized care based on molecular profiles. This shift addresses the critical need to identify non-responders to expensive biologics at an early stage, thereby optimizing clinical outcomes and reducing financial waste. A significant step in this direction was highlighted by Scipher Medicine in June 2025, when they announced that an AI-driven algorithm had analyzed real-world data from nearly 1,500 rheumatoid arthritis patients to identify clinical measures that accurately predict therapy success. Such innovations allow physicians to choose the most effective mechanism of action for a patient's unique biology, advancing beyond generalized treatment guidelines.

Concurrently, there is a strong trend toward integrating digital health tools designed to enhance real-time symptom monitoring and improve medication adherence. As disease management increasingly depends on complex self-administered regimens, mobile applications are becoming essential for bridging the gap between clinical appointments and daily self-care, although sustaining long-term engagement remains a challenge. A study published in Rheumatology International in December 2025 evaluated 2,036 adult users and found that only 25.8% met the criteria for sustained adherence over a 12-week period. This finding underscores the industry's growing focus on developing more intuitive, patient-centric digital platforms to ensure that the clinical benefits of prescribed therapies are fully realized through consistent usage.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG

Report Scope

In this report, the Global Rheumatoid Arthritis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatoid Arthritis Drugs Market, By Type of Molecule

• Pharmaceuticals
• Biopharmaceuticals

Rheumatoid Arthritis Drugs Market, By Drug Class

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• disease-modifying antirheumatic drugs (DMARDs)
• Corticosteroids
• Analgesics
• Other

Rheumatoid Arthritis Drugs Market, By Distribution Channel

• Prescription
• Over the counter (OTC)

Rheumatoid Arthritis Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatoid Arthritis Drugs Market.

Available Customizations:

Global Rheumatoid Arthritis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatoid Arthritis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Molecule (Pharmaceuticals, Biopharmaceuticals)
  • 5.2.2. By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), Corticosteroids, Analgesics, Other)
  • 5.2.3. By Distribution Channel (Prescription, Over the counter (OTC))
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Rheumatoid Arthritis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Molecule
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rheumatoid Arthritis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Molecule
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Rheumatoid Arthritis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Molecule
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Rheumatoid Arthritis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Molecule
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Rheumatoid Arthritis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Molecule
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Rheumatoid Arthritis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Molecule
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Rheumatoid Arthritis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Molecule
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Rheumatoid Arthritis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Molecule
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Rheumatoid Arthritis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Molecule
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Rheumatoid Arthritis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Molecule
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Rheumatoid Arthritis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Molecule
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Rheumatoid Arthritis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Molecule
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Rheumatoid Arthritis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Molecule
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Rheumatoid Arthritis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Molecule
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Rheumatoid Arthritis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Molecule
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Rheumatoid Arthritis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Molecule
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Rheumatoid Arthritis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Molecule
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Rheumatoid Arthritis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Molecule
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Rheumatoid Arthritis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Molecule
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Rheumatoid Arthritis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Molecule
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Rheumatoid Arthritis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Molecule
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Rheumatoid Arthritis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Molecule
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Rheumatoid Arthritis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Molecule
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Rheumatoid Arthritis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Molecule
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Rheumatoid Arthritis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Bayer AG
• 15.4. Boehringer Ingelheim GmbH
• 15.5. Bristol-Myers Squibb Company
• 15.6. Celgene Corporation
• 15.7. F. Hoffmann-La Roche AG
• 15.8. Johnson & Johnson
• 15.9. Merck & Co. Inc.
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer